Pregnancy Rates in Women with Diminished Ovarian Reserve (DOR) Undergoing IVF. A 10 Year Experience Using DHEA Supplementation

author.DisplayName 1,2 author.DisplayName 1,2,3 author.DisplayName 1,4
1Toronto West Fertility Center, Etobicoke, ON, Canada
2Department of Obstetrics and Gynecology, University of Toronto, Canada
3Department of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Toronto, Canada
4Clinical Nutrition and Risk Factor Modification Center, St. Michael's Hospital, Canada

Introduction: DHEA has been suggested to have a beneficial effect on implantation, pregnancy rate and to reduce pregnancy loss rates, but its recommendation is still controversial. Our objective is to report pregnancy rate per embryo transfer (PR/ET), clinical pregnancy rate per ET (CPR/ET) and live birth rate (LBR) in women with DOR undergoing IVF treatment with DHEA supplementation.

Methods: In a retrospective study (February 2006-February 2016), we collected information on 166 DHEA-supplemented IVF cycles in women with DOR. We excluded cycles in women ≥44 years old, frozen cycles, and donor cycles. We divided the cycles by age groups: <35yo, 35-39yo, and 40-≤43yo. PR/ET included chemical pregnancies. CPR/ET was defined as an intra uterine pregnancy on ultrasound at 4 weeks post ET. Statistical analyses were performed using STATA version 11.1.

Results: A total of 166 DHEA-supplemented IVF cycles were included, 25 cycles in women <35yo, 71 cycles in women 35-39yo, and 70 cycles in women 40-≤43yo. For the three different age groups, the cancellation rate was 20%(n=5), 19.7%(n=14), and 25.7%(n=18). Even though the PR/ET was not statistically significant amongst the age groups, 30%(n=6), 50.9%(n=28), and 31.4%(n=16), p=0.08, we did see a beneficial trend for the 35-39yo group. The CPR/ET was 25%(n=5), 47.3%(n=26), and 31.4%(n=16), p=0.11. The LBR was 20%(n=4), 36.4%(n=20), 21.6%(n=11), p=0.17.

Conclusion: The use of DHEA supplementation in our 10-year practice experience in women with DOR undergoing IVF treatment had no statistical significance on PR/ET, CPR/ET and LBR. However, the CPR/ET was higher in our clinic than in the reported Canadian ART (CARTR) 2013 registry for women at risk for DOR (40-42 years old [23.4%]). Overall, the use of DHEA in women with DOR undergoing IVF treatment should not be dismissed and should be investigated in randomized well controlled trials.









Powered by Eventact EMS